From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy

Dermatol Ther. 2021 Jan;34(1):e14565. doi: 10.1111/dth.14565. Epub 2020 Nov 30.


COVID-19 generates a complex systemic inflammatory response that can lead to death due to wide macrophage activation, endothelial damage, and coagulation in critically ill patients. SARS-CoV-2-induced lung injury due to inflammatory mediated thrombosis could be similar to the livedoid vasculopathy in the skin, supporting a translational comparison of these clinical settings. In this article, we discuss anticoagulation, suppression of inflammatory response, and hyperbaric oxygen therapy in the context of severe COVID-19 and livedoid vasculopathy.

Keywords: COVID-19; heparin; hyperbaric oxygenation; livedoid; thrombosis; vasculopathy.

Publication types

  • Review

MeSH terms

  • Anticoagulants / adverse effects
  • COVID-19* / complications
  • Heparin, Low-Molecular-Weight
  • Humans
  • Hyperbaric Oxygenation*
  • Inflammation / therapy
  • SARS-CoV-2
  • Skin Diseases / etiology*


  • Anticoagulants
  • Heparin, Low-Molecular-Weight